SymbioCellTech announced the publication of a paper demonstrating the potency and efficacy of its innovative and proprietary human Neo-Islet™ in a third, clinically relevant model of human Type 1 Diabetes.
[SymbioCellTech (GlobeNewswire, Inc.)]
Sorry, but the selected Zotpress account can't be found.